Companies:

 

Articles:

 
Biotech

Argent BioPharma Signs $15m Deal to Acquire Key Clinical and IP Assets from AusCann

Go to Nik Hill author's page
By Nik Hill - 
Argent BioPharma ASX RGT Acquire Key Clinical IP Assets AusCann
Copied

Argent BioPharma (ASX: RGT) has signed a binding term sheet to acquire the key assets of AusCann Group Holdings, a deal designed to expand its clinical pipeline, intellectual property (IP) portfolio, and European presence.

The US$15 million scrip-based transaction will see AusCann receive 25 million Argent shares at US$0.60 each, with completion expected in the September quarter.

Argent said the acquisition aligns with its strategy to build a global, IP-led pharmaceutical platform and supports its planned dual listing on a US national exchange.

Transformational Asset Package

The acquisition covers AusCann’s Neuvis drug delivery platform, an FDA-facing pre-clinical epilepsy dataset, a 48% stake in CannPal Animal Therapeutics, and a 19.99% stake in ECC Pharm.

Neuvis is a patented oral capsule technology that offers three to five times higher bioavailability than standard formats, providing a pathway for next-generation versions of Argent’s lead drugs CannEpil and CimetrA.

The package also brings access to EU-GMP manufacturing and German pharmaceutical distribution channels, including more than 3,000 pharmacies across Europe.

Single Scalable Platform

Managing director Roby Zomer said the deal consolidated IP, manufacturing and distribution into a single scalable platform.

“We are building a capital-efficient engine to deliver next-generation formulations of CannEpil and CimetrA—at scale, with speed, and with enduring IP protection,” Mr Zomer said.

“It positions Argent to expand globally while strengthening our core pipeline.”

Strategic Synergies

Argent believes the CannPal asset provides a comprehensive toxicology and pharmacokinetics data suite that can accelerate US regulatory filings and reduce costs.

The ECC Pharm holding secures vertically integrated European production capacity, projected to cut the cost of goods for CannEpil and CimetrA by more than 50%.

Distribution subsidiaries Medtradix and Cannaport offer bonded logistics and quality release across the EU, strengthening Argent’s route to market.

Clear Commercial Benefits

AusCann executive director Andrew Chapman, who will join Argent’s board after the transaction, said the assets deliver clear regulatory and commercial benefits.

“I know these assets well—and I’ve seen first-hand the value they unlock,” Mr Chapman said.

“From IP to revenue to regulatory readiness, this is a strategic acquisition that accelerates Argent’s pathway to a successful dual national listing in the US.”

The acquisition remains subject to shareholder and regulatory approvals, with integration activities already mapped to support clinical expansion and launch readiness later this year.